<DOC>
	<DOCNO>NCT01441934</DOCNO>
	<brief_summary>Although pulmonary hypertension ( PH ) quite frequent complication advance pulmonary disease , independent prognostic factor , evidence-based treatment approach exist patient . This study address drug sildenafil low pulmonary vascular resistance patient significant pulmonary hypertension ( high blood pressure lung ) associate chronic obstructive pulmonary disease ( COPD ) . It see treatment improve effort capacity , quality life without cause deterioration pulmonary gas exchange ( mainly arterial oxygenation ) . Patients 18 year age old moderate COPD pulmonary hypertension ( mean pulmonary arterial pressure &gt; 30 mmHg ) may eligible study . Participants randomly assign receive sildenafil placebo ( pill drug ) 16 week . Before start treatment ( baseline ) , end study , patient comprehensive assessment include : - chest x-ray CT scan ( baseline ) ; - pulmonary function test measure much air patient breathe , capacity diffusion gas ; - arterial blood gas analysis ( safety reason examination perform baseline , randomization one hour administration tablet ( 20 mg ) sildenafil , every month ) - echocardiogram ( heart ultrasound ) ( baseline ) ; - 6-minute walk test measure exercise capacity ; - quality-of-life assessment ( SF-36 questionnaire ) - right heart catheterization evaluate severity hypertension At end 16-week period , patient may opt continue receive sildenafil monitor open-label phase study 1 year .</brief_summary>
	<brief_title>SPHERIC-1 . Sildenafil Pulmonary HypERtension In COPD</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Patient affect stable COPD optimal treatment , chronic oxygen therapy patient hypoxia , PaO2 rest ≥ 60 mmHg PaCO2≤ 55 mmHg , age 18 80 year old : Group 1 : BPCO GOLD I‐III ( post bronchodilator FEV1 ≥ 30 % , FEV1/FVC ≤ 0,7 , TLC ≥ 70 % ) + PAPm ≥ 30 mmHg PCP &lt; 15 mmHg Group 2 : BPCO GOLD IV ( post bronchodilator FEV1 &lt; 30 % , FEV1/FVC ≤ 0,7 , TLC ≥ 70 % ) + PAPm ≥ 35 mmHg PCP &lt; 15 mmHg Different type pulmonary hypertension ( chronic , thromboembolic pulmonary hypertension , pulmonary arterial hypertension etc . ) Significant leave cardiac disease ( LVEF &lt; 45 % , cardiomyopathy , valvulopathy , unstable coronaropathy ) Treatment nitrate last 10 day , need nitrate therapy different disease Treatment specific drug arterial pulmonary hypertension ( le 4 week ) Significant systemic disease COPD Recent exacerbation chronic bronchitis ( &lt; 4 week ) Pregnancy breastfeeding , woman without adequate contraceptive method whole study duration History anaphylaxis allergic reaction 5phosphodiesterase inhibitor Cancers within last 5 year exception localize cancer skin cervix Hepatic insufficiency chronic renal failure hemoglobinemia &lt; 10 g/dL screen phase Contraindications subministration per SPC Mental disorder , alcohol abuse , chronic alcoholism , drug abuse Subjects unable sign inform consent form Subjects unable walk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>